Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1984 1
1985 3
1986 6
1987 1
1988 3
1989 8
1990 4
1991 13
1992 33
1993 51
1994 101
1995 75
1996 88
1997 65
1998 65
1999 73
2000 74
2001 57
2002 78
2003 70
2004 100
2005 68
2006 74
2007 60
2008 56
2009 72
2010 96
2011 97
2012 77
2013 74
2014 76
2015 85
2016 65
2017 81
2018 91
2019 104
2020 143
2021 177
2022 186
2023 156
2024 129
2025 173
2026 116

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,955 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Chihara D, et al. J Clin Oncol. 2020 May 10;38(14):1527-1538. doi: 10.1200/JCO.19.02250. Epub 2020 Feb 28. J Clin Oncol. 2020. PMID: 32109194 Free PMC article. Clinical Trial.
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. ...CONCLUSION: Achieving MRD-free CR of HCL after first-line cladribine is greatly enhanced by concurrent rituximab and less …
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 …
Cladribine (Mavenclad) for multiple sclerosis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Jul 29;61(1577):118-120. Med Lett Drugs Ther. 2019. PMID: 31381552 Review. No abstract available.
Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions.
Hermann R, Krajcsi P, Fluck M, Seithel-Keuth A, Bytyqi A, Galazka A, Munafo A. Hermann R, et al. Clin Pharmacokinet. 2022 Feb;61(2):167-187. doi: 10.1007/s40262-021-01089-9. Epub 2021 Dec 11. Clin Pharmacokinet. 2022. PMID: 34894346 Free PMC article. Review.
Other efficient transporters of cladribine are the ABC efflux transporters, specifically breast cancer resistance protein, which likely modulates the oral absorption and renal excretion of cladribine. ...This article reviews the existing knowledge on inhibitors of N …
Other efficient transporters of cladribine are the ABC efflux transporters, specifically breast cancer resistance protein, which like …
Cladribine (2-chlorodeoxyadenosine).
Beutler E. Beutler E. Lancet. 1992 Oct 17;340(8825):952-6. doi: 10.1016/0140-6736(92)92826-2. Lancet. 1992. PMID: 1357355 Review. No abstract available.
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P. Giovannoni G, et al. Mult Scler. 2018 Oct;24(12):1594-1604. doi: 10.1177/1352458517727603. Epub 2017 Sep 5. Mult Scler. 2018. PMID: 28870107 Free article. Clinical Trial.
OBJECTIVE: To assess the safety and efficacy of cladribine treatment in a 2-year Extension study. METHODS: In this 2-year Extension study, placebo recipients from CLARITY received cladribine 3.5 mg/kg; cladribine recipients were re-randomized 2:1 to cladri …
OBJECTIVE: To assess the safety and efficacy of cladribine treatment in a 2-year Extension study. METHODS: In this 2-year Extension s …
[Cladribine].
Ogura M. Ogura M. Gan To Kagaku Ryoho. 2003 Feb;30(2):309-17. Gan To Kagaku Ryoho. 2003. PMID: 12610885 Review. Japanese.
Cladribine (2-chlorodeoxyadenosine: 2-CdA) is a chlorinated purine analogue that is resistant to degradation by adenosine deaminase. ...The agent was synthesized and has been investigated extensively by researchers at the Scripps Clinic and Research Foundation in the Unite …
Cladribine (2-chlorodeoxyadenosine: 2-CdA) is a chlorinated purine analogue that is resistant to degradation by adenosine deaminase. …
Cladribine: mechanisms and mysteries in multiple sclerosis.
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Jacobs BM, et al. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1266-1271. doi: 10.1136/jnnp-2017-317411. Epub 2018 Jul 10. J Neurol Neurosurg Psychiatry. 2018. PMID: 29991490 Review.
The pharmacology of cladribine explains how it is selectively toxic towards lymphocytes. Immunophenotyping studies show that cladribine depletes lymphocyte populations in vivo with a predilection for B cells. In vitro studies demonstrate that cladribine also …
The pharmacology of cladribine explains how it is selectively toxic towards lymphocytes. Immunophenotyping studies show that cladr …
Cladribine Tablets: A Review in Relapsing MS.
Deeks ED. Deeks ED. CNS Drugs. 2018 Aug;32(8):785-796. doi: 10.1007/s40263-018-0562-0. CNS Drugs. 2018. PMID: 30105527 Free PMC article. Review.
Cladribine is a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, key cells underlying multiple sclerosis (MS) pathogenesis. Cladribine tablets (Mavenclad( )) represent the first short-course oral disease-modifying drug (DMD) for use in MS. . …
Cladribine is a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, key cells underlying multiple sclerosis (MS …
Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
Giovannoni G. Giovannoni G. Neurotherapeutics. 2017 Oct;14(4):874-887. doi: 10.1007/s13311-017-0573-4. Neurotherapeutics. 2017. PMID: 29168160 Free PMC article. Review.
Cladribine is a purine nucleoside analogue that selectively depletes peripheral lymphocytes without a major impact on cells of the innate immune system. ...Oral cladribine is effective in relapsing forms of multiple sclerosis. As a selective immune reconstitution th …
Cladribine is a purine nucleoside analogue that selectively depletes peripheral lymphocytes without a major impact on cells of the in …
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
Qasrawi A, Bahaj W, Qasrawi L, Abughanimeh O, Foxworth J, Gaur R. Qasrawi A, et al. Ann Hematol. 2019 Mar;98(3):561-579. doi: 10.1007/s00277-018-3562-8. Epub 2018 Nov 23. Ann Hematol. 2019. PMID: 30470874 Review.
Recent clinical trials and retrospective studies explored the addition of cladribine to standard induction chemotherapy for AML. Some of these studies showed higher rates of complete remission, and one showed improved survival. In this review, we will discuss the antileuke …
Recent clinical trials and retrospective studies explored the addition of cladribine to standard induction chemotherapy for AML. Some …
2,955 results